The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

atritech.net

Total Raised

$91.82M

Investors Count

12

Deal Terms

5

Atritech Funding, Atritech Valuation & Atritech Revenue

7 Fundings

Atritech's latest funding round was a Unattributed for $30M on March 13, 2009.

Atritech's valuation in September 2007 was $96.45M.

Atritech's latest post-money valuation is from March 2009.

Sign up for a free trial to see Atritech's valuations in March 2009, March 2006 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

3/13/2009

Unattributed

$30M

$99M

0

FY undefined

9/7/2007

Series D

$99M

$96.45M

0

FY undefined

0

3/13/2006

Series C

$99M

$99M

0

FY undefined

0

10/17/2003

Series B

$99M

0

FY undefined

0

4/1/2001

Unattributed - II

$99M

0

FY undefined

0

Date

3/13/2009

9/7/2007

3/13/2006

10/17/2003

4/1/2001

Round

Unattributed

Series D

Series C

Series B

Unattributed - II

Amount

$30M

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$96.45M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

0

0

0

Atritech Deal Terms

5 Deal Terms

Atritech's deal structure is available for 5 funding rounds, including their Unattributed from March 13, 2009.

Round

Unattributed

Series D

Series C

Series B

Series A

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

$99M

Post-Money Valuation

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

$99M

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

$99M

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

$99M

$99M

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Unattributed

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Atritech Investors

12 Investors

Atritech has 12 investors. Affinity Capital Management invested in Atritech's Series D funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/17/2003

3/13/2009

4
Unattributed, Series B (2003), Series C (2006), Series D (2007)

Venture Capital

Minnesota

3/13/2006

3/13/2009

4
Unattributed, Other Investors (0), Series C (2006), Series D (2007)

Private Equity

Connecticut

3/13/2006

3/13/2009

3
Unattributed, Series C (2006), Series D (2007)

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Split Rock Partners

Subscribe to see more

Venture Capital

Minnesota

00/00/0000

00/00/0000

Vector Capital

Subscribe to see more

Private Equity

California

First funding

10/17/2003

3/13/2006

3/13/2006

00/00/0000

00/00/0000

Last Funding

3/13/2009

3/13/2009

3/13/2009

00/00/0000

00/00/0000

Investor

Split Rock Partners

Vector Capital

Rounds

4
Unattributed, Series B (2003), Series C (2006), Series D (2007)
4
Unattributed, Other Investors (0), Series C (2006), Series D (2007)
3
Unattributed, Series C (2006), Series D (2007)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Private Equity

Venture Capital

Venture Capital

Private Equity

Location

Minnesota

Connecticut

Massachusetts

Minnesota

California

You May Also Like

M
MetaCure

MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.

W
Windy Hill Medical

Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

C
Cardiophotonics

Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration

C
CoRepair

CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

S
Salutaris Medical Devices

Salutaris Medical Devices (SalutarisMD) is a clinical-stage medical device company developing an investigational ophthalmic treatment for Wet Age-related Macular Degeneration (Wet AMD). SalutarisMD is developing a minimally invasive procedure that can be performed in an outpatient or physician office setting in approximately 15 minutes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.